fluconazole has been researched along with Bacteremia in 24 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of fluconazole prophylaxis to prevent invasive candida infections in patients with acute leukaemia receiving chemotherapy is not clear." | 7.74 | Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia. ( Anttila, VJ; Elonen, E; Juvonen, E; Nihtinen, A; Ruutu, T; Volin, L, 2008) |
| " The purpose of this study was to delineate the effects of fluconazole on systemic hemodynamics and on microanatomy of the heart, lung, liver, and kidney parenchyma of swine during graded bacteremia." | 7.69 | The cardiopulmonary, eicosanoid, and tissue microanatomic effects of fluconazole during graded bacteremia. ( Catalano, E; Gallucci, J; Quinn, J; Salartash, K; Slotman, G, 1996) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 5.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| "The efficacy of fluconazole prophylaxis to prevent invasive candida infections in patients with acute leukaemia receiving chemotherapy is not clear." | 3.74 | Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia. ( Anttila, VJ; Elonen, E; Juvonen, E; Nihtinen, A; Ruutu, T; Volin, L, 2008) |
| " The purpose of this study was to delineate the effects of fluconazole on systemic hemodynamics and on microanatomy of the heart, lung, liver, and kidney parenchyma of swine during graded bacteremia." | 3.69 | The cardiopulmonary, eicosanoid, and tissue microanatomic effects of fluconazole during graded bacteremia. ( Catalano, E; Gallucci, J; Quinn, J; Salartash, K; Slotman, G, 1996) |
| "Both cancer centers differed in prophylactic antibiotic policies." | 2.69 | Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998) |
| "Fungal infections are a major problem in patients with hematologic malignancy." | 2.68 | Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. ( Schaffner, A; Schaffner, M, 1995) |
| "Bloodstream Candida infection is a life-threatening event among ICU admitted patients." | 1.56 | Necessity to identify candida species accurately with minimum inhibitory concentration determination in each case of bloodstream infections. ( Gupta, MK; Pandey, N; Paul, P; Tilak, R, 2020) |
| "One patient developed Fusarium infection." | 1.40 | Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country. ( Adil, SN; Ali, N; Shaikh, MU, 2014) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 1.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Monzani, V | 1 |
| Córdoba, S | 1 |
| Vivot, M | 1 |
| Arias, B | 1 |
| Vivot, W | 1 |
| Szusz, W | 1 |
| Castellaro, P | 1 |
| Appendino, A | 1 |
| Taverna, CG | 1 |
| Pandey, N | 1 |
| Gupta, MK | 1 |
| Paul, P | 1 |
| Tilak, R | 1 |
| Blennow, O | 1 |
| Ljungman, P | 1 |
| Sparrelid, E | 1 |
| Mattsson, J | 1 |
| Remberger, M | 1 |
| Ali, N | 1 |
| Adil, SN | 1 |
| Shaikh, MU | 1 |
| Guery, BP | 1 |
| Arendrup, MC | 2 |
| Auzinger, G | 1 |
| Azoulay, E | 1 |
| Borges Sá, M | 1 |
| Johnson, EM | 1 |
| Müller, E | 1 |
| Putensen, C | 1 |
| Rotstein, C | 1 |
| Sganga, G | 1 |
| Venditti, M | 1 |
| Zaragoza Crespo, R | 1 |
| Kullberg, BJ | 1 |
| Cervera, C | 1 |
| Linares, L | 1 |
| Reverté, E | 1 |
| Escorsell, A | 1 |
| Moreno, A | 1 |
| Holzknecht, BJ | 1 |
| Thorup, J | 1 |
| Andersen, SE | 1 |
| Steensen, M | 1 |
| Hesselfeldt, P | 1 |
| Nielsen, JM | 1 |
| Knudsen, JD | 1 |
| Vinekar, A | 1 |
| Avadhani, K | 1 |
| Maralusiddappa, P | 1 |
| Prabhu, VM | 1 |
| Mahendradas, P | 1 |
| Indumathi, VA | 1 |
| Castagnola, E | 1 |
| Machetti, M | 1 |
| Bucci, B | 1 |
| Viscoli, C | 1 |
| Lee, JS | 1 |
| Shin, JH | 1 |
| Lee, K | 1 |
| Kim, MN | 1 |
| Shin, BM | 1 |
| Uh, Y | 1 |
| Lee, WG | 1 |
| Lee, HS | 1 |
| Chang, CL | 1 |
| Kim, SH | 1 |
| Shin, MG | 1 |
| Suh, SP | 1 |
| Ryang, DW | 1 |
| Nihtinen, A | 1 |
| Anttila, VJ | 1 |
| Elonen, E | 1 |
| Juvonen, E | 1 |
| Volin, L | 1 |
| Ruutu, T | 1 |
| Negroni, R | 1 |
| Maiolo, E | 1 |
| Arechavala, AI | 1 |
| Bianchi, MH | 1 |
| Santiso, G | 1 |
| Schaffner, A | 1 |
| Schaffner, M | 1 |
| Kunová, A | 3 |
| Trupl, J | 3 |
| Dluholucký, S | 1 |
| Galová, G | 1 |
| Krcméry, V | 4 |
| Narang, PK | 1 |
| Trapnell, CB | 1 |
| Schoenfelder, JR | 1 |
| Lavelle, JP | 1 |
| Bianchine, JR | 1 |
| Broun, ER | 1 |
| Wheat, JL | 1 |
| Kneebone, PH | 1 |
| Sundblad, K | 1 |
| Hromas, RA | 1 |
| Tricot, G | 1 |
| Salartash, K | 1 |
| Gallucci, J | 1 |
| Quinn, J | 1 |
| Catalano, E | 1 |
| Slotman, G | 1 |
| Oravcová, E | 1 |
| Pichna, P | 1 |
| Kukucková, E | 1 |
| Grausova, S | 1 |
| Grey, E | 1 |
| Spanik, S | 1 |
| Demitrovicová, A | 1 |
| Kralóvicová, K | 1 |
| Lacka, J | 1 |
| Krupova, I | 2 |
| Svec, J | 1 |
| Koren, P | 1 |
| Kaiserova, E | 1 |
| Foltinova, A | 1 |
| Kovacicova, G | 1 |
| Kiskova, M | 1 |
| Krchnakova, A | 1 |
| West, D | 1 |
| Krupova, Y | 1 |
| Novotny, J | 1 |
| Sabo, A | 1 |
| Mateicka, F | 1 |
| Presterl, E | 1 |
| Lassnigg, A | 1 |
| Mueller-Uri, P | 1 |
| El-Menyawi, I | 1 |
| Graninger, W | 1 |
| Dimick, JB | 1 |
| Pelz, RK | 1 |
| Consunji, R | 1 |
| Swoboda, SM | 1 |
| Hendrix, CW | 1 |
| Lipsett, PA | 1 |
| Persson, L | 1 |
| Vikerfors, T | 1 |
| Sjöberg, L | 1 |
| Engervall, P | 1 |
| Tidefelt, U | 1 |
| Safdar, A | 1 |
| van Rhee, F | 1 |
| Henslee-Downey, JP | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study[NCT00934934] | Phase 2 | 61 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to slow enrollment) | ||
| Short Daily Alcohol Locks for the Prevention of Tunneled Catheter Infection in Patients With Haematological Disease. Randomised Placebo Controlled Trial[NCT00122642] | Phase 2/Phase 3 | 440 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure (NCT00934934)
Timeframe: post randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 5.9 |
| Antifungal | 5.9 |
Number of days free of antibiotic use within the first 28 days (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 16 |
| Antifungal | 10 |
(NCT00934934)
Timeframe: 28 days
| Intervention | pg/ml (Mean) |
|---|---|
| VAP withCandida | 116 |
| VAP Without Candida | 129.1 |
(NCT00934934)
Timeframe: 28 days
| Intervention | mg/l (Mean) |
|---|---|
| VAP withCandida | 133 |
| VAP Without Candida | 145.7 |
Measure of the duration of participant stay in the ICU (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 11.5 |
| Antifungal | 13 |
Measure of the duration of the participant's hospital stay (NCT00934934)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Placebo | 29 |
| Antifungal | 28 |
Number of days free of ICU (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 14 |
| Antifungal | 4 |
(NCT00934934)
Timeframe: 28 days
| Intervention | pg/ml (Mean) |
|---|---|
| VAP withCandida | 97.5 |
| VAP Without Candida | 3 |
Overall recruitment rate per site (NCT00934934)
Timeframe: 32 months
| Intervention | participants per site /month (Number) |
|---|---|
| Overall | 0.6 |
(NCT00934934)
Timeframe: 28 days
| Intervention | ng/ml (Mean) |
|---|---|
| VAP withCandida | 3.0 |
| VAP Without Candida | 22.5 |
Number of days in ICU free of ventilation (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 8 |
| Antifungal | 9 |
2 reviews available for fluconazole and Bacteremia
| Article | Year |
|---|---|
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment.
Topics: Amphotericin B; Antifungal Agents; Bacteremia; Candida albicans; Candidiasis; Fluconazole; Humans; I | 2009 |
Antifungal prophylaxis with azole derivatives.
Topics: Antifungal Agents; Azoles; Bacteremia; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; M | 2004 |
4 trials available for fluconazole and Bacteremia
| Article | Year |
|---|---|
Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
Topics: Adult; Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Bacteremia; Candidi | 1995 |
Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.
Topics: Acyclovir; Adult; Bacteremia; Bone Marrow Transplantation; Female; Fever; Fluconazole; Gram-Positive | 1994 |
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A | 1998 |
Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit.
Topics: Aged; Antifungal Agents; APACHE; Bacteremia; Baltimore; Catheterization, Central Venous; Cohort Stud | 2001 |
18 other studies available for fluconazole and Bacteremia
| Article | Year |
|---|---|
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R | 2020 |
Necessity to identify candida species accurately with minimum inhibitory concentration determination in each case of bloodstream infections.
Topics: Amphotericin B; Antifungal Agents; Bacteremia; Candida; Candida tropicalis; Candidiasis; Caspofungin | 2020 |
Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anti-Infective Agents; Bacteremia; Candidiasis; Child; Chil | 2014 |
Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Topics: Acyclovir; Adolescent; Adult; Anti-Infective Agents; Bacteremia; Candida albicans; Candidiasis; Cath | 2014 |
Case report 6: Candidaemia in a high risk liver transplant recipient.
Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Bacteremia; Bronchitis; Candida albicans; C | 2010 |
Decreasing candidaemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis*.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Ba | 2011 |
Retinal vasculitis as an early indicator of systemic candidal abscesses in a premature infant.
Topics: Abscess; Antifungal Agents; Bacteremia; Candida albicans; Candidiasis; Eye Infections, Fungal; Fluco | 2011 |
Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
Topics: Antifungal Agents; Azoles; Bacteremia; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; H | 2007 |
Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia.
Topics: Adult; Bacteremia; Candidiasis; Fluconazole; Humans; Leukemia; Retrospective Studies | 2008 |
[Clinical cases in medical mycology. Case no. 32].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Bacteremia; Bronchoalveolar | 2008 |
Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species.
Topics: Antifungal Agents; Bacteremia; Bronchoalveolar Lavage Fluid; Candida; Candidiasis; Fluconazole; Huma | 1995 |
Fluconazole and enhanced effect of rifabutin prophylaxis.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Bacteremia; Drug Synergism; Fluconazole; H | 1994 |
The cardiopulmonary, eicosanoid, and tissue microanatomic effects of fluconazole during graded bacteremia.
Topics: Anesthesia; Animals; Anti-Inflammatory Agents; Antifungal Agents; Bacteremia; Cell Nucleus; Eicosano | 1996 |
Resistance pattern of 2816 isolates isolated from 17631 blood cultures and etiology of bacteremia and fungemia in a single cancer institution.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteremia; Cephal | 1997 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu | 1998 |
Cytokines in sepsis due to Candida albicans and in bacterial sepsis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Bacteremia; Candidias | 1999 |
Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 2000 |
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Topics: Adolescent; Adult; Antifungal Agents; Bacteremia; Bone Marrow Transplantation; Candida; Candidiasis; | 2001 |